Matches in Wikidata for { <http://www.wikidata.org/entity/Q90952140> ?p ?o ?g. }
Showing items 1 to 40 of
40
with 100 items per page.
- Q90952140 description "article scientifique publié en 2019" @default.
- Q90952140 description "artículu científicu espublizáu n'ochobre de 2019" @default.
- Q90952140 description "scientific article published on 25 October 2019" @default.
- Q90952140 description "wetenschappelijk artikel" @default.
- Q90952140 description "наукова стаття, опублікована 25 жовтня 2019" @default.
- Q90952140 name "Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma" @default.
- Q90952140 name "Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma" @default.
- Q90952140 type Item @default.
- Q90952140 label "Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma" @default.
- Q90952140 label "Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma" @default.
- Q90952140 prefLabel "Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma" @default.
- Q90952140 prefLabel "Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma" @default.
- Q90952140 P1433 Q90952140-028FEA84-790F-480F-A042-6560553493BC @default.
- Q90952140 P1476 Q90952140-CB3949D5-8A8E-4653-A656-A7F460AA1375 @default.
- Q90952140 P2093 Q90952140-3E3F66BB-F9E0-4D39-9843-C8BD6D1AD7EF @default.
- Q90952140 P2093 Q90952140-68A2C459-E5E7-4B2C-9E36-597DDCE69B8E @default.
- Q90952140 P2093 Q90952140-98E4DA0F-8102-4B38-8A20-CD7304B5FFD0 @default.
- Q90952140 P2093 Q90952140-99B23FC6-BAE4-4FE2-8D2E-2709802FBBD5 @default.
- Q90952140 P2093 Q90952140-9ED10643-363B-4C45-B118-B1BEA9AE5E8D @default.
- Q90952140 P31 Q90952140-2A0BF1DD-9739-483A-A5D3-5C177C51A3CF @default.
- Q90952140 P356 Q90952140-6F230BF5-90D5-4A59-AD2E-109E175E3CF3 @default.
- Q90952140 P50 Q90952140-A1557819-6AA4-475D-81C9-35F9DEA72889 @default.
- Q90952140 P577 Q90952140-956A9CCB-4448-4167-87BB-C4F0C6C89163 @default.
- Q90952140 P698 Q90952140-299C3259-9749-4ACE-B0A0-53866C1892DB @default.
- Q90952140 P921 Q90952140-D2D2EAD4-6C85-428B-BEC6-19E3802E2B12 @default.
- Q90952140 P356 S10637-019-00864-7 @default.
- Q90952140 P698 31654285 @default.
- Q90952140 P1433 Q2312231 @default.
- Q90952140 P1476 "Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma" @default.
- Q90952140 P2093 "Anthony Wood" @default.
- Q90952140 P2093 "Nabil Adra" @default.
- Q90952140 P2093 "Nur Damayanti" @default.
- Q90952140 P2093 "Saby George" @default.
- Q90952140 P2093 "Sreenivasulu Chintala" @default.
- Q90952140 P31 Q13442814 @default.
- Q90952140 P356 "10.1007/S10637-019-00864-7" @default.
- Q90952140 P50 Q90952138 @default.
- Q90952140 P577 "2019-10-25T00:00:00Z" @default.
- Q90952140 P698 "31654285" @default.
- Q90952140 P921 Q1164529 @default.